Out with the old, in with the nucleus
Are you tired of binging reruns on Netflix? Maybe you need a break from reality TV but you’re not sure where to turn for high-quality entertainment? Look no further — the nucleus has it all. There’s mystery, murder, machines of extraordinary complexity and visually stunning landscapes.
Stories in nuclear signaling are unraveling at an unprecedented pace thanks to technological and conceptual advances in chemistry, biochemistry and cell biology. Our speakers will address long-standing questions about organism development, cellular identity and the genetic basis for disease.
Submit an abstract
Abstract submission begins Sept. 14. If you submit by Oct. 12, you'll get a decision by Nov. 1. The regular submission deadline is Nov. 30. See the categories.
You will hear about how cutting-edge interdisciplinary approaches are being used to uncover new regulatory mechanisms underlying transcription, genome structure, and other phenomena in the nucleus. We will also discuss how rapid progress in the field is inspiring new therapeutic approaches for diseases related to dysfunctional nuclear processes.
You don’t want to miss this — even the cytosol junkies will be on the edge of their seats.
Keywords: Enzyme mechanism, genetics and disease, chemical probes, transcription regulation, chromatin modifications, genome structure.
Who should attend: You. Our speakers span a wide breadth of biological phenomena, scientific disciplines and technologies. We have something for everyone. Current projections: standing room only.
Your session’s theme song: “Journey to the Island” by John Williams
This song is about the most important genetics experiment ever performed.
This session is powered by “hot, nasty, bad-*ss speed.” — Eleanor Roosevelt, Talladega Nights
Signaling mechanisms in the nucleus
Chemical strategies to study nuclear processes
Chair: Aaron Johnson
Anna Mapp, University of Michigan
Glen Liszczak, University of Texas Southwestern Medical Center
Oliver Bell, University of Southern California Kerk School of Medicine
Minkui Luo, Memorial Sloan Kettering Cancer Center
Chromatin organization, replication and repair
Chair: Katharine Diehl
Aaron Streets, University of California, Berkeley
Aaron Johnson, University of Colorado Anschutz Medical Campus
Carl Wu, Johns Hopkins University
Serena Sanulli, Stanford University
Chromatin modifications in the nucleus
Chair: Glen Liszczak
Alex Ruthenberg, University of Chicago
Katharine Diehl, University of Utah
Tim Stasevich, Colorado State University
Phil Cole, Harvard University
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Mass spec method captures proteins in native membranes
Yale scientists developed a mass spec protocol that keeps proteins in their native environment, detects intact protein complexes and tracks drug binding, offering a clearer view of membrane biology.
Laser-assisted cryoEM method preserves protein structure
University of Wisconsin–Madison researchers devised a method that prevents protein compaction during cryoEM prep, restoring natural structure for mass spec studies. The approach could expand high-resolution imaging to more complex protein systems.
Method sharpens proteome-wide view of structural changes
Researchers developed a method that improves limited proteolysis coupled with mass spectrometry, separating true changes from abundance or splicing effects.
Discoveries made possible by DNA
The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.
Unraveling the language of histones
Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.
How Alixorexton could transform narcolepsy treatment
A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.